Agreement aims to expand access for researchers to proteomic biomarker discovery platform.
Agilent Technologies Inc.(CA ,USA) and SomaLogic Inc. (CO, USA) recently announced an agreement regarding SomaLogic’s protein biomarker discovery platform. As part of the agreement, the SOMAscan microarray-based assay, which already includes Agilent microarrays in its workflow, will be placed in several academic and contract research centers.
The assay is available as a service to researchers direct from SomaLogic; however, this new incentive aims to meet growing demand for access to SomaLogic’s proteomic assay. Jacob Thaysen, Vice President and general manager of Agilent’s Genomics Solutions Division commented on the agreement,”This agreement will greatly enhance our current microarray offerings by expanding them into the rapidly growing proteomics market. SomaLogic’s cutting-edge proteomic technology makes them an ideal partner for us to increase our presence in this growing market.”
“Agilent’s custom microarrays have been a critical element in our development of the SOMAscan assay over the past several years,” stated Larry Gold, chairman and Chief Executive Officer of SomaLogic. “We are delighted that our partnership is expanding to make the technology even more accessible to researchers everywhere.”